Lupin receives $50 million from Boehringer Ingelheim for achievement of key milestones

In a regulatory filing Lupin announced "the achievement of key milestones for Lupin's MEK inhibitor compound (LNP3794) that is planned for development by Boehringer Ingelheim in combination as potential targeted therapy for patients with difficult-to-treat cancers."

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3oVlsaH
via IFTTT